Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001415889-17-000282
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-02-16 19:06:35
Reporting Period:
2017-02-14
Filing Date:
2017-02-16
Accepted Time:
2017-02-16 19:06:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1454276 O Terrence Moore 3611 Valley Centre Drive, Suite 300
San Diego CA 92130
Evp, Chief Commercial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-02-14 87,128 $19.61 90,759 No 4 M Direct
Common Stock Disposition 2017-02-14 89,088 $39.69 1,671 No 4 S Direct
Common Stock Acquisiton 2017-02-15 1,700 $19.61 3,371 No 4 M Direct
Common Stock Disposition 2017-02-15 1,700 $39.65 1,671 No 4 S Direct
Common Stock Acquisiton 2017-02-16 17,421 $19.61 19,092 No 4 M Direct
Common Stock Acquisiton 2017-02-16 19,687 $27.20 38,779 No 4 M Direct
Common Stock Acquisiton 2017-02-16 29,644 $34.45 68,423 No 4 M Direct
Common Stock Disposition 2017-02-16 66,752 $39.88 1,671 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2017-02-14 12,747 $0.00 12,747 $19.61
Common Stock Stock Option (right to buy) Disposition 2017-02-14 74,381 $0.00 74,381 $19.61
Common Stock Stock Option (right to buy) Disposition 2017-02-15 1,700 $0.00 1,700 $19.61
Common Stock Stock Option (right to buy) Disposition 2017-02-16 17,421 $0.00 17,421 $19.61
Common Stock Stock Option (right to buy) Disposition 2017-02-16 19,687 $0.00 19,687 $27.20
Common Stock Stock Option (right to buy) Disposition 2017-02-16 29,644 $0.00 29,644 $34.35
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,649 2023-08-18 No 4 M Direct
55,223 2023-08-18 No 4 M Direct
53,523 2023-08-18 No 4 M Direct
36,102 2023-08-18 No 4 M Direct
13,125 2024-03-06 No 4 M Direct
90,356 2025-03-19 No 4 M Direct
Footnotes
  1. Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.72 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
  4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.38 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
  5. 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
  6. 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
  7. 25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.